Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

[bennevisplace]

Just published in the NEJM nejm.org/doi/full/10.1056/N...

Interim results from the COMET-ICE phase 3, placebo-controlled clinical trial of Sotrovimab for nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression.

Bottom line: drug efficacy was estimated at 85 %, with no safety issues.

Note that "severely immunosuppressed" patients were excluded from the study.

These results were reported as a pre-print in May and were the basis of an EUA in the US and marketing authorisation in the EU.

Sotrovimab, though not yet approved in the UK, is undergoing clinical trial in the UK together with a partner drug VIR-7832 agiletrial.net/first-patien...

[bennevisplace]

Here is a link to an audio discussion between NEJM editors, topics include Sotrovimab and the role of monoclonal antibodies in Covid (approx. 8-15 minutes in). nejm.org/doi/full/10.1056/N...